AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 132 min read$TAK

Plump Andrew Stewart sold $2.8M of TAK

Plump Andrew Stewart (President, R&D) sold 165,393 shares of TAKEDA PHARMACEUTICAL CO LTD (TAK) at $17.10 ($2.83M total) on 2026-08-10.

Original reporting
SEC EDGAR · Plump Andrew Stewart
Published Aug 13, 2026, 1:50 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 2:02 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TAK
Neutral
medium confidence
Mentioned
$TAK
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TAKNeutralLow
01

Why it matters

This provides a fresh, primary-source datapoint on insider selling activity, but it does not include any new company-specific business or financial developments.

02

Market read

Traders may monitor insider activity as a sentiment input, but the filing alone is unlikely to drive a fundamental repricing.

03

What to watch

The filing does not state reasons for the sale, and the share price level ($17.10) may reflect normal trading rather than a new valuation signal.

Relevance 6/10Novelty 3/10Timing: filed Aug 12, transaction dated Aug 10 (insider sale disclosure)

Background

The article is an SEC Form 4 insider transaction disclosure for Takeda Pharmaceutical Co Ltd (TAK).

Company-level read

Ticker impact

$TAKNeutralMedium confidence
Context

Takeda disclosed an insider open-market sale by its R&D President, Andrew Stewart, of 165,393 shares at $17.10 on Aug 10.

Expected impact

Likely limited, short-lived sentiment impact; no clear directional catalyst from the filing alone.

Evidence & confidence

Form 4 shows an open-market sale and explicitly notes no pre-arranged 10b5-1 plan, but it does not provide new operational, financial, or regulatory information.

Market effects

Sector

Minimal; insider sale does not change sector fundamentals or guidance.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The absence of a 10b5-1 plan could be interpreted as less “mechanical,” but insider sales are still often driven by diversification or personal liquidity needs.

Key entities

  • issuer
    TAK

    Takeda Pharmaceutical Co Ltd, the subject of the Form 4 insider transaction.

  • insider
    Plump Andrew Stewart

    President, R&D at Takeda, reported an open-market sale of shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TAK insider trading history →

Related articles

OCT 26
$AZNMedAI 8/10

AstraZeneca: Stomach Cancer Drug With $3 to $5 Billion Sales Potential, and One Significant Wrinkle

AstraZeneca (AZN) reported that its drug sone-ve doubled median survival in stomach cancer patients who had already tried at least two treatments, with median survival rising from 5.0 to 10.0 months. The company expects peak annual sales of $3B to $5B. Takeda (TAK) also reported positive results for its rival drug, arcotatug tavatecan, meeting both primary endpoints.

finance.yahoo.com3 min
OCT 23
$TAKHighAI 9/10

Takeda reports positive phase 3 trial results for gastric cancer drug

Takeda Pharmaceutical (TSE:4502/NYSE:TAK) reported positive Phase 3 trial results for arcotatug tavatecan in gastric cancer patients, meeting overall and progression-free survival endpoints. Median overall survival was 10.2 months vs. 6.9 months for other treatments. The drug showed a 37.4% objective response rate. Takeda plans regulatory filings in Japan and China. The drug is not yet approved by the FDA.

investing.com2 min
OCT 19
$TAKLowAI 8/10

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication

Takeda's VERDICT trial showed that treating ulcerative colitis patients with ENTYVIO to achieve disease clearance (vs. symptomatic remission) prolonged time to complications by 70%. The study met its primary endpoint, with Group 3 (disease clearance) showing longer time to complications (HR 0.33, P=0.0014). Over 50% of patients in Group 3 achieved their target by Week 16. The trial also identified molecular patterns associated with early disease clearance.

elliotlakestandard.ca2 min